A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

NCT00445094 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection
Pneumonia

Interventions

DRUG: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
DRUG: Comparator: amikacin / Duration of Treatment: 3 Days
DRUG: Comparator: tazocin / Duration of Treatment: 3 Days
DRUG: Comparator: vancomycin / Duration of Treatment: 3 Days

Sponsor

Merck Sharp & Dohme LLC